Clearside Biomedical Q1 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $230.000K Miss $585.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Clearside Biomedical (NASDAQ:CLSD) reported Q1 2024 GAAP EPS of $(0.17), missing the $(0.14) estimate, and sales of $230K, missing the $585K estimate. This represents a 13.33% decrease in EPS and a 5.65K% increase in sales year-over-year.
May 09, 2024 | 9:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Clearside Biomedical reported a larger than expected Q1 2024 loss and significantly missed sales estimates, with a notable year-over-year sales increase.
Missing both EPS and sales estimates significantly, especially in a quarter, indicates potential operational or market challenges. The substantial miss on sales estimates and the increase in losses compared to the previous year could lead to negative investor sentiment in the short term, potentially impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100